Followers | 116 |
Posts | 13850 |
Boards Moderated | 0 |
Alias Born | 03/16/2014 |
Saturday, February 19, 2022 1:47:36 PM
“We are deeply disappointed that the studies did not achieve their symptomatic endpoints,” said Robert Alexander, PhD, Chief Executive Officer of Allakos. “The company is grateful to the patients with eosinophilic gastrointestinal diseases (EGIDs) and to the investigators who participated in the ENIGMA and KRYPTOS trials.”
Recent ALLK News
- Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/14/2024 08:02:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:05:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 09:22:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 10:52:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:05:11 PM
- Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024 • GlobeNewswire Inc. • 02/26/2024 12:02:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 10:00:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 10:00:20 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2024 12:08:46 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:01:45 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:34:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 12:07:55 PM
- Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition • GlobeNewswire Inc. • 02/12/2024 12:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 09:05:10 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/02/2024 05:31:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 10:00:10 PM
- Allakos Announces a Restructuring to Focus on Development of AK006 • GlobeNewswire Inc. • 01/16/2024 12:02:00 PM
- Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints • GlobeNewswire Inc. • 01/16/2024 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/05/2024 09:02:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 11:00:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 11:00:17 PM
FEATURED Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM